Rate My Professor Jennifer Cochran

The Cochran laboratory uses interdisciplinary approaches in chemistry, engineering, and biophysics to study complex biological systems and develop new tools for basic science and biomedical applications, with translational interests in protein-based drug discovery and development for oncology and regenerative medicine, including wound healing, cardiac tissue regeneration, and cancer imaging and therapy. Research focuses on elucidating molecular details of receptor-mediated cell signaling and engineering protein and peptide-based therapeutics and diagnostic agents. Major awards include election to the National Academy of Engineering in 2025, College of Fellows of the American Institute for Medical and Biological Engineering in 2018, Hellman Faculty Scholar Award in 2008, Martin D. Abeloff Scholar Award in 2008, Kimmel Scholars Award in 2007, Mallinckrodt Faculty Scholar Award in 2007, and Howard Temin Award in 2004. Key publications include "Engineered CD47 protects T cells for enhanced antitumour immunity" (Nature, 2024), "Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function" (Proceedings of the National Academy of Sciences of the United States of America, 2024), "An engineered NKp46 antibody for construction of multi-specific NK cell engagers" (Protein engineering, design & selection, 2024), "Enhanced safety and efficacy of protease-regulated CAR-T cell receptors" (Cell, 2022), and "An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy" (Communications biology, 2021).